Belmar Pharma Solutions publishes NAD+ product information alongside a patient insert covering injectable, nasal, sublingual, and troche forms. The insert is dated March 1, 2026 and provides more practical information than a short wellness catalog description. It still needs to be read in relation to the preparation actually prescribed.
We checked the public product page and insert on September 19, 2026. We did not order a prescription or evaluate Belmar’s dispensing performance. This review considers how the documents can help a patient ask better questions, while identifying why broad instructions for several forms cannot replace a product-specific label.
Belmar’s insert is useful background, but the actual pharmacy label and prescriber instructions must identify the selected route, formulation, and handling requirements.
The product family contains distinct preparations
The Belmar product page links to information about NAD+ and a separate patient insert. The insert lists several compounded forms. Those options should not be treated as one medicine with a single price, handling rule, or expected effect.
Ask the prescriber and pharmacist to identify the selected formulation and the reason for its route. Our route comparison guide explains why choosing a spray instead of an injection changes the questions you need answered. A shared ingredient name does not establish interchangeable evidence or instructions.
The route wording needs to match the prescription
The insert contains general injectable wording that mentions more than one route and then a more specific section describing subcutaneous use. If that creates uncertainty, have the pharmacist and clinician reconcile it for the actual preparation. A review should not decide which generic paragraph overrides another for an individual patient.
Use the label-reading guide to identify the details that need clarification. The route, concentration, prescribed amount, and supplied equipment should be understandable together. If the label and accompanying material seem inconsistent, resolve that before using the medication rather than adapting instructions from another product.
Storage depends on the form you receive
Belmar’s insert distinguishes handling information for troches from its nasal and injectable preparations and directs readers to the prescription label. That is a useful reminder that a broad NAD+ storage rule is not enough. Ask the pharmacist for the instructions and usable dates attached to your actual order.
If medication is shipped, ask how a delay or temperature concern is assessed and who authorizes a replacement. The pharmacy verification guide helps organize those product questions. A patient should not have to infer the suitability of a delivered parcel from a general webpage or the condition of an ice pack alone.
The supplier document is not a complete cost quote
We did not establish an all-in treatment price from the reviewed Belmar pages. The prescribing service may charge separately for visits, testing, medication, supplies, and delivery. The pharmacy’s product information helps explain the preparation, but it does not determine what an online program or local clinic will bill.
Ask for the full quote from the service arranging your care and identify the pharmacy charge within it if available. Our cost guide explains why two services using a similar supplier can have different total costs. The comparison should include follow-up and payment terms, not just the medication line.
Read the references and safety information in context
Belmar links research about NAD-related biology and therapeutic interest. That material does not establish that every listed preparation produces a particular clinical benefit. Ask the prescriber what evidence supports the selected form and intended use, particularly if your goal involves a persistent symptom or a diagnosed condition.
The evidence guide explains that distinction. The patient insert also includes reactions and escalation information, which should be reviewed with the clinical team rather than treated as an exhaustive prediction of what will happen. Compounded drugs are not FDA-approved, even when a supplier provides a detailed patient document.
Compare Belmar at the supplier level
The AnazaoHealth review examines another supplier with multiple formats. MediVera and Hallandale provide useful comparisons for premixed injectable listings. None of these reviews establishes that the products are interchangeable or that one pharmacy’s preparation has better clinical outcomes.
If you are choosing a telehealth service, review its clinical and billing arrangements separately, including our CoreAge Rx review of the featured commercial partner. This Belmar review does not assert a supply relationship with that brand. Its purpose is to help you evaluate the documentation when Belmar is the pharmacy actually named in your treatment plan.
Follow the source
References & further reading
- Belmar Pharma Solutions — NAD+ product information
Checked September 19, 2026. Supplier product and research information, separate from a clinician service or completed order.
- Belmar — NAD+ patient insert
Checked September 19, 2026. Document dated March 1, 2026. Multiple forms and route wording require prescription-specific clarification.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.